checkAd

    CellaVision AB  314  0 Kommentare Interim report January-September 2018 - Seite 3

    About CellaVision
    CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replaces manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the market support organizations in the US, Canada, China, Sweden, Japan, United Arab Emirates, South Korea, Australia, France, Germany, Brazil, Great Britain, Mexico and India. In 2017, sales were SEK 309 million and the company's growth target is 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com




    Lesen Sie auch

    This announcement is distributed by West Corporation on behalf of West Corporation clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: CellaVision AB via Globenewswire

    Seite 3 von 3




    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    CellaVision AB Interim report January-September 2018 - Seite 3 Continued strong performance in all regions July 1-September 30, 2018 Net sales increased by 37 % to SEK 84.3 million (61.3). Organic growth increased to 33 % (-11). Operating profit increased to SEK 21.0 million (10.2). The operating margin …